Jpmorgan Chase & CO Regenxbio Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Regenxbio Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,477,311 shares of RGNX stock, worth $18.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,477,311
Previous 3,012,476
17.76%
Holding current value
$18.9 Million
Previous $35.2 Million
26.27%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding RGNX
# of Institutions
196Shares Held
43MCall Options Held
104KPut Options Held
478K-
Black Rock Inc. New York, NY8.61MShares$65.6 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.89MShares$37.3 Million3.36% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.37MShares$33.3 Million0.0% of portfolio
-
State Street Corp Boston, MA2.78MShares$21.2 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.35MShares$10.3 Million0.0% of portfolio
About REGENXBIO Inc.
- Ticker RGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,230,000
- Market Cap $329M
- Description
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...